Press release on General Assembly voting results

integragen

The mixed shareholders’ general meeting of IntegraGen was held on Thursday, June 13, 2019 at the Bedford Hotel’s premises at 17 rue de l’Arcade in Paris.

At the end of the Combined General Meeting, (…)  » 

IntegraGen Reports 2018 Annual Results

integragen

IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019.

Click here to view press release.

 

 

IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test

IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked  diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.

(…)  » 

IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers

IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools.

(…)  » 

IntegraGen Reports Financial Results for 1st Half of 2018

IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.

Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57% vs. (…)  » 

IntegraGen Announces Publication of miR-31-3p Data in Clinical Cancer Research

IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…)  » 

The SeqOIA Cooperative Health Group selects IntegraGen as the operator of its sequencing platform as part of the France Genomic Medicine 2025 Plan

integragen

IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the Gustave Roussy Cancer Center, (…)  »